HOME > ARCHIVE
ARCHIVE
- Many Doctors See Problems with GE Drugs: JMA
September 25, 2006
- PFSB to Draft GL for Registered Drug Sellers' Examination
September 25, 2006
- GENERIC NEWS IN BRIEF
September 25, 2006
- Zaditen Capsules Approved as Switch-OTC Drug
September 25, 2006
- TMRC Increasing Focus on Drug Discovery, Development: Dr Ekimoto
September 25, 2006
- Stomach Cancer Risk 10 Times Higher in H. pylori-Positive People
September 25, 2006
- SRI Int'l to Expand Business in Japan
September 25, 2006
- Asahi Kasei Files for ART-123 in Japan, Licenses It to Artisan Pharma Overseas
September 18, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 18, 2006
- Korosho Calls For Tax Break for Unapproved Drugs, Bio-hazard Measures
September 18, 2006
- Eisai Acquires 4 Oncology Products from Ligand
September 18, 2006
- REGULATORY NEWS IN BRIEF
September 18, 2006
- MEETING 65th JCA Annual Meeting to Be Held Sept. 28-30
September 18, 2006
- NEW PRODUCTS Novartis Pharma: Voltaren Tape L
September 18, 2006
- Bayer's Rivaroxaban Shows Efficacy in PII Trials
September 18, 2006
- Innovation Is Driven by Free Trade: Mr Taurel of Eli Lilly
September 18, 2006
- Toray, JT, and Torii to Codevelop the Antipruritic TRK-820
September 18, 2006
- SELF-MEDICATION NEWS IN BRIEF
September 18, 2006
- TMRC Expands Drug Development System
September 18, 2006
- Takara Bio Licenses Retronectin to MSKCC in the US
September 18, 2006
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
